D
David Richard Walwyn
Researcher at University of Pretoria
Publications - 58
Citations - 560
David Richard Walwyn is an academic researcher from University of Pretoria. The author has contributed to research in topics: Procurement & Developing country. The author has an hindex of 10, co-authored 54 publications receiving 468 citations. Previous affiliations of David Richard Walwyn include University of Cambridge & Council of Scientific and Industrial Research.
Papers
More filters
Journal ArticleDOI
Renewable energy gathers steam in South Africa
TL;DR: The Renewable Energy Independent Power Producers Procurement Programme (the REI4P) is an extensive initiative to install 17.8 GW of electricity generation capacity from renewables over the period 2012-2030.
Journal ArticleDOI
An l-arabinan from apple-juice concentrates
Shirley C. Churms,Edwin H. Merrifield,Alistair M. Stephen,David Richard Walwyn,Alfred Polson,Kirsten J. van der Merwe,H. S. C. Spies,Nino Costa +7 more
Journal ArticleDOI
Techno-Economic Analysis of Horseradish Peroxidase Production Using a Transient Expression System in Nicotiana benthamiana
TL;DR: Production scale, protein yield and biomass productivity are found to be the most important determinants of overall viability.
Journal ArticleDOI
The role of South African traditional health practitioners in the treatment of HIV/AIDS : a study of their practices and use of herbal medicines
TL;DR: Although some progress is evident, THP approaches to HIV treatment fails to conform to minimum standards proposed by the World Health Organisation and other organisations, and represents a considerable challenge to the integration of THPs with the biomedical sector, and with the antiretroviral treatment programme in South Africa.
Journal ArticleDOI
Patents and profits : a disparity of manufacturing margins in the tenofovir value chain
TL;DR: Analysis of the TDF value chain, from preparation of the active pharmaceutical ingredient (API) to sale of the formulated product, shows that manufacturing margins are highly skewed in favour of the originator, which argues for a more rational approach to drug pricing including possible regulation in developed countries and more sustainable margins for the generic producers.